Pradeep Rajagopalan (@PatchPradeep) header
Pradeep Rajagopalan (@PatchPradeep) profile picture

Respiratory, Sleep & General Medicine Physician | FRACP, FRCP, FCCP | Clinical Trials PI | TUH & JCU | Advocate for precision care & digital health

Townsville, Queensland
Joined November 2010
Photo by Pradeep Rajagopalan (@PatchPradeep)Photo by Pradeep Rajagopalan (@PatchPradeep)Photo by Pradeep Rajagopalan (@PatchPradeep)Photo by Pradeep Rajagopalan (@PatchPradeep)Photo by Pradeep Rajagopalan (@PatchPradeep)Photo by Pradeep Rajagopalan (@PatchPradeep)Photo by Pradeep Rajagopalan (@PatchPradeep)Photo by Pradeep Rajagopalan (@PatchPradeep)Photo by Pradeep Rajagopalan (@PatchPradeep)Photo by Pradeep Rajagopalan (@PatchPradeep)
“Why can’t I stop the fibrosis?” “Why is this pill giving me diarrhoea?” “Do these drugs *really* work?” Patients with IPF or progressive ILD ask these 5 tough questions. Let’s break them down — with honesty, evidence, and a dose of hope.🧵 #FIBRONEER #IPF #PulmonaryFibrosis #Nerandomilast #MedTwitter
1
4
323
Pradeep Rajagopalan retweeted
Experienced doctors do not always show their commitment through enthusiasm. Sometimes scepticism reflects years of seeing what works, what fails, and what organisations are in danger of forgetting, writes @docib bmj.com/content/395/bmj-2026…
11
3
44
4,980
Interested in the latest perspectives on lung cancer screening? Register now for this upcoming webinar for a summary and discussion of the IARC Perspective on Lung Cancer Screening, published in the New England Journal of Medicine. 📅 Date: 23 November
2
2
3
70
Pradeep Rajagopalan retweeted
A new single-cell atlas of non-small-cell #LungCancer found that standard staging alone can get a patient's risk wrong, in both directions. A quarter of people staged as stage I were actually high risk. A small group of stage IV patients had survival as good as early stage disease. This is exactly the point Lung Cancer Europe has long made through its Get Checked! campaign: a stage label is not the whole picture. Full story: lungcancereurope.eu/news/why…
2
38
2
130
8,231
【The Spectrum of Tuberculosis from Infection to Disease】 @HeartlandNTBC & @MayoClinicINFD 👉Really useful resource for all clinicians (PDF available online for FREE)! 👉heartlandntbc.org/wp-content… #TBIntensive #IDFellow #IDMedEd
1
34
1
95
5,032
Pradeep Rajagopalan retweeted
What environmental and occupational exposures are risk factors for the development of interstitial lung disease (ILD) and should be included on ILD-specific exposure questionnaires? Read the original research in #Journal_CHESTPulm: hubs.la/Q04yrPZN0 #MedEd #JournalCHEST #LungDisease #LungHealth
5
13
1,253
Pradeep Rajagopalan retweeted
Patients with lung cancers with cystic airspaces had 5-year cancer-specific survival comparable to noncystic non–small cell lung cancers, and retrospective simulations suggested that low-dose CT Lung-RADS 2022 recommendations enabled earlier diagnosis. bit.ly/4k8WpiR
8
53
3,066
Pradeep Rajagopalan retweeted
In this targeted editorial, Drs. Byrne and Hammer discuss lung cancer associated with cystic airspaces, including the application of Lung-RADS 2022. Read more here ➡️ bit.ly/4fhXHEP
1
3
9
2,049
Pradeep Rajagopalan retweeted
The Pulmonary Embolism Reporting and Data System (PE-RADS) provides a standardized framework for reporting acute pulmonary embolism at CT scan and MR angiography to guide treatment considerations based on clot location and right heart imaging features. Read the article in the November issue of the journal CHEST®: hubs.la/Q04CvMpr0 #MedEd #JournalCHEST
2
11
64
3,742
NPJ Primary Care ✍️ The European respiratory society guideline for adult bronchiectasis 2025: summary and implementation guide for primary care #OpenAccess #Bronchiectasis #Nature Read the article: doi.org/10.1038/s41533-026-0…
6
10
497
Pradeep Rajagopalan retweeted
The latest CHEST How I Do It discusses factors that can influence eosinophil counts and provides practical considerations for identifying underlying type 2 inflammation in patients with COPD in the clinic. Read more: hubs.la/Q04Cvn7T0 #MedEd #JournalCHEST #COPD
1
5
14
967
Pradeep Rajagopalan retweeted
Different nailfold capillary changes in Rheumatic disease #ACR26
10
32
1,065
Pradeep Rajagopalan retweeted
HOW TO READ A CT SCAN - simple approach 👇🏼 behindtheknife.org/watch/beh…
2
178
945
43,311
Pradeep Rajagopalan retweeted
IgG4 Guidelines👇
🔥Hot off the press for #ACR26 🔥 The @IgG4ward foundation guidelines on the treatment of IgG4-related disease thelancet.com/journals/lanrh… Free to read on lancet.com
30
107
6,700
Pradeep Rajagopalan retweeted
Thank you to Dr Ajay Wagh for an excellent presentation today on Advances in the Management of Recurrent Pleural Effusions! 🎥 Watch: drericlim.com/brompton-grand… 🎧 Listen: open.spotify.com/show/1mgh6u… 🔔 Subscribe: creators.spotify.com/pod/sho…
1
4
198
Pradeep Rajagopalan retweeted
Patients who used #depemokimab for uncontrolled #asthma experienced improved symptoms, activity, impact on daily life and well-being through 52 weeks, according to a poster presented at the #CHEST Annual Meeting. healio.com/news/allergy-asth…
6
6
150